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number of activated proliferating MCs and attenuated the glo-Pentoxifylline attenuates experimental mesangial proliferative
merular mRNA levels of type I (a1), type III (a1), and typeglomerulonephritis.
IV (a1) collagen and fibronectin compared with vehicle-treatedBackground. Accumulation of glomerular macrophages, pro-
nephritic rats.liferation of mesangial cells (MCs), and deposition of extracel-
Conclusion. The administration of PTX to rats with anti-lular matrix proteins are pathobiological hallmarks of glomeru-
Thy1 disease reduces accumulation and proliferation of glo-lonephritis. We previously reported that a clinically available
merular macrophages, attenuates proteinuria, suppresses acti-nonselective inhibitor of cyclic 39,59-nucleotide phosphodies-
vation and proliferation of MCs, and ameliorates glomerularterase, pentoxifylline (PTX), inhibits proliferation of cultured
sclerosis. These results suggest that PTX may have a sup-rat MCs, as well as collagen production by these cells. In this
pressive effect in acute phases or relapses of mesangial prolifer-study, we investigated the in vivo effects of PTX on rat anti-
ative glomerulonephritis.
Thy1 disease, a model of mesangial proliferative nephritis.
Methods. Anti-Thy1 nephritis was induced in Sprague-Dawley
rats by injecting mouse anti-rat Thy1 antibodies intravenously.
Nephritic rats were randomly assigned to receive PTX (0.1 Influx and accumulation of circulating monocytes in
g/kg/day) or vehicle (phosphate-buffered saline) and were sac- the glomerular mesangium and their transformation into
rificed at various time points. Paraffin kidney sections were tissue macrophages are implicated in the pathogenesis
stained with hematoxylin and periodic acid-Schiff reagents for of many glomerular diseases caused by immunological
glomerular histology. Frozen kidney sections were stained by
and nonimmunological injuries. Monocytes infiltratingmonoclonal antibodies against proliferating cell nuclear antigen,
glomeruli secrete an array of proinflammatory cytokinesED-1, and a-smooth muscle actin and were visualized by color
and growth factors, which trigger a downstream cascadedevelopment from a horseradish peroxidase reaction. Mono-
cyte chemoattractant protein-1 (MCP-1), intercellular adhesion of glomerular injury. The resultant proliferation of resi-
molecule-1 (ICAM-1), and various extracellular matrix mRNAs dent glomerular cells, primarily the mesangial cells
were analyzed by Northern blotting. Urine protein concentra- (MCs), and deposition of extracellular matrix proteins
tions were determined by Lowry’s method. can lead to progressive glomerulosclerosis and end-stageResults. Nephritic rats treated with PTX excreted less uri-
renal disease if not treated [1–5]. Because of the per-nary protein on day 5 of nephritis than vehicle-treated nephritic
ceived importance of monocyte infiltration, MC prolifer-rats. In periodic acid-Schiff–stained kidneys from PTX-treated
ation, and extracellular matrix deposition in glomerularnephritic rats, there was attenuation of both glomerular cellu-
larity and glomerular sclerosis compared with vehicle-treated diseases, considerable effort has been devoted to the
nephritic rats. PTX decreased the augmented glomerular mRNA development of novel and effective pharmacotherapies
levels of MCP-1 and ICAM-1 at two hours and on day 1 of targeted against these processes.
nephritis. Immunoreactive staining showed that PTX reduced
Anti-Thy1 nephritis, which is induced with antibodythe number of proliferating glomerular macrophages on days
to the Thy-1 antigen present on MCs, is an experimental1, 2, and 3, but not at two hours of nephritis, compared with
model that closely simulates human mesangial prolifera-vehicle-treated nephritic rats. On day 5, PTX decreased the
tive glomerulonephritis. The early pathobiological cellu-
lar events are characterized by invasion of platelets, poly-
morphonuclear leukocytes, and monocytes into theKey words: anti-Thy1 glomerulonephritis, mesangial cell, monocyte/
macrophage, intercellular adhesion molecule-1, extracellular matrix. glomerulus, which occurs within hours after the induc-
tion of nephritis. Complement-dependent mesangiolysisReceived for publication October 23, 1998
then ensues between days 1 and 3. This is followed byand in revised form March 10, 1999
Accepted for publication April 1, 1999 a rebound proliferation of MCs, which begins on day 3
and peaks between days 5 and 10. Finally, the excess 1999 by the International Society of Nephrology
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Fig. 1. Flow diagram of the experiments ex-
amining the effects of pentoxifylline (PTX)
on rats with anti-Thy1 nephritis.
MCs regress by apoptosis during the repairing process In this study, we hypothesized that the administration
of PTX in vivo might ameliorate anti-Thy1 nephritis byover the next two to three weeks [6–12]. Parallel to
reducing the accumulation of monocytes, the prolifera-these cellular events, a number of proteins that mediate
tion of MCs, and the deposition of extracellular matrixmigration of monocytes, growth of MCs, and accumula-
in the glomerulus.tion of extracellular matrix are either expressed de novo
or up-regulated in the glomerulus of this nephritic model
[7, 10, 12–18]. Various therapeutic agents have been em- METHODS
ployed to ameliorate the severity of anti-Thy1 nephritis. Disease model and experimental protocol
These include anti-transforming growth factor (TGF)-b1 Male Wistar rats weighing 180 to 200 g were obtained
antiserum [19], decorin [20], anti-platelet-derived growth from the animal center of our institute. Six groups of
factor (PDGF) antibody [17], heparin [21], an inhibitor rats were studied (Fig. 1). The control rats (group A,
of nitric oxide synthase (NG-monomethyl-l-arginine) N 5 15) received only 0.2 ml of 1 3 phosphate-buffered
[22], selective blockers of phosphodiesterase isozymes saline (PBS; pH 7.4) at the beginning of day 1. The
(lixazinone and rolipram) [23], a matrix metalloprotein- nephritic rats (group B, N 5 15) received 250 mg of a
ase inhibitor (BB-1101) [24], and angiotensin II blockade mouse anti-rat Thy1 (CD90) monoclonal antibody (lyo-
(lisinopril or an angiotensin II receptor antagonist, philized ascites; Cedarlane, Ontario, Canada) in 0.2 ml
L-158,809) [25]. Except for the latter, none of these mea- of 1 3 PBS at the beginning of day 1 and were treated
sures are currently available for clinical use. with vehicle (1 3 PBS) from day 22 to day 5. Groups
Pentoxifylline (PTX) is a phosphodiesterase inhibitor C to F were treated with the same dose of anti-Thy1
antibody as group B, plus various regimens of PTX asthat has been used clinically for therapy of patients with
follows: PTX (0.1 g/kg/day) from day 3 to day 5 (groupperipheral vascular diseases [26, 27]. In addition to its
C, N 5 5); PTX (0.1 g/kg/day) from day 22 to day 21well-known hemorrheological activity, in vitro studies
(group D, N 5 5); PTX (0.1 g/kg/day) from day 22 tohave shown that PTX inhibits formation of tumor necro-
day 5 (group E, N 5 15); and PTX (0.1 g/kg/day) fromsis factor-a (TNF-a), which plays a key role in inflamma-
day 1 to day 5 (group F, N 5 5). Anti-Thy1 antibodytory responses [28, 29]. Recent studies also found that
was given by intrajugular venous injection, whereas PTXPTX suppressed expression of intercellular adhesion
and vehicle were administered by intrajugular venousmolecule-1 (ICAM-1) by monocytes and lymphocytes
infusion over a period of two hours.[30, 31]. Furthermore, PTX inhibits proliferation of cul-
All animals in groups A to F were killed at the end
tured lymphocytes [29], fibroblasts [32, 33], and MCs [34] of day 5 of nephritis. Renal tissue from five rats in each
and suppresses the production of extracellular matrix group were examined for glomerular histopathology.
proteins, such as collagen, by these cells [33, 34]. In Ten rats in groups A, B, and E, together with three
experimental models, PTX has been shown to protect separate sets of rats (10/group) that received treatments
against endotoxin shock [29], delay the onset of allergic identical to those of groups A, B, and E, but were killed
encephalomyelitis [35], and halt the fibrotic process in at two hours, day 1, and day 3, respectively, were used
hepatic fibrosis [36]. Taken together, these data raise for immunohistochemical double staining and isolation
the possibility that PTX might have promise as an anti- of glomerular total RNA. The investigation complied
with the standards delineated in the Guide for the Careinflammatory, anti-proliferative, and anti-fibrotic agent.
Chen et al: PTX and anti-Thy1 nephritis934
and Use of Laboratory Animals, published by the U.S.
National Institutes of Health (Bethesda, MD, USA).
Renal glomerular histopathology
Tissues for glomerular histology were fixed in 10%
formalin, and 6 mm paraffin sections were stained with
periodic acid-Schiff (PAS) reagent and hematoxylin. The
percentages of glomeruli exhibiting segmental/global
sclerosis were assessed by examination of 50 glomeruli,
with similar cross-sectional diameters, per animal, and
were graded on a scale of 0 to 3 as follows: grade 0
(normal, no positive stains per glomerulus); grade 1 (mild
changes, ,25% positive stains per glomerulus); grade 2
(moderate changes, 25 to 50% positive stains per glomer-
ulus); and grade 3 (severe changes, .50% positive stains
per glomerulus). Glomerular sclerosis was scored semi-
quantitatively in each group of animals by multiplying
the scale (ranging from 0 to 3) by the number of glomer-
uli, and total scores were calculated by the sum of individ-
ual products in each group of five rats. Glomerular hyper-
cellularity was assessed on the basis of total glomerular
cells per glomerular cross section. Two hundred and fifty
glomeruli (50 glomeruli per animal) were counted for
each group of five rats.
Immunohistochemical double staining
Frozen tissue sections were used for immunoperoxi-
dase staining. Briefly, after perfusing the heart with 150
ml of ice-cold 4% paraformaldehyde (PFA) in 1 3 PBS,
rat kidneys were removed and cut coronally into 4 mm
thick slices and immersed in 4% PFA at 48C overnight.
The next day, PFA solutions were decanted, and the tis-
sues were immersed in 30% sucrose at 48C overnight.
Tissues were then embedded in Tissue-Tekt O.C.T. com-
pound (Miles Inc., Elkhart, IN, USA) in isopentane in liq-
uid nitrogen and stored at 2708C until cryostat sectioning.
Fig. 2. Effects of pentoxifylline (PTX) on renal function on day 5 (A),Immunohistochemical double staining was performed
and urinary protein excretion on day 1 and day 5 (B) of anti-Thy1by first staining the sections for proliferating cells with nephritis. (A) Control rats (h); vehicle-treated anti-Thy1 nephritic rats
a mouse anti-proliferating cell nuclear antigen (PCNA; (j); nephritic rats treated with PTX on days 22 to 5 (group E, ).
Abbreviations are: SCr, serum creatinine levels; CCr, creatinine clearance.Dakopatts, Glostrup, Denmark), followed by staining
(B) Control rats (h; group A), vehicle-treated anti-Thy1 nephritic ratswith either a mouse anti-rat ED-1 (monocytes/macro- (d; group B), PTX-treated anti-Thy1 nephritic rats (s; group C), PTX-
phages) monoclonal antibody (Chemicon, Temecula, CA, treated anti-Thy1 nephritic rats (n; group D), PTX-treated anti-Thy1
nephritic rats (.; group E), PTX-treated anti-Thy1 nephritic rats (e;USA), or a mouse anti-rat a-smooth muscle actin mono-
group F). *P , 0.05, relative to group B.clonal antibody (Sigma, St. Louis, MO, USA). Briefly,
8 mm renal sections were microwaved (model Tatung
TMO-6810) in 0.01 m citrate buffer, pH 6.0, for two five-
minute periods at 800 W to retrieve the antigens. The bated with biotin-conjugated anti-mouse or anti-rabbit
IgG for one hour at RT. The sections were then incu-sections were then treated with 0.5% hydrogen peroxi-
dase in 1 3 PBS for 20 minutes at room temperature bated with the avidin-biotin-peroxidase reagent for an-
other one hour at RT according to the manufacturer’s(RT) to block the endogenous peroxidase. Sections were
subsequently blocked with 10% normal goat serum for instructions (Dakopatts). After three 10-minute washes
in 1 3 PBS/0.1% Triton X-100 at RT, the reactions on30 minutes at RT, and primary antibodies were then
added followed by incubation at 48C overnight. The fol- sections were detected with peroxidase substrate con-
taining 3-amino-9-ethylcarbazole chromogen (AEC, forlowing day, sections were washed three times in 1 3
PBS/0.1% Triton X-100 for 10 minutes and were incu- PCNA staining) or diaminobenzidine chromogen (DAB)
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Table 1. Effect of pentoxifylline (PTX) on total glomerular cells and glomerular sclerosis scores in anti-Thy1 nephritic rats on day 15
Group A Group B Group C Group D Group E Group F
Total glomerular cells 62.861.3 88.462.0a 85.462.2a 79.862.5ab 75.761.5ac 76.961.8ac
Glomerular sclerosis
Grade 0 245 (98) 11 (4.4) 27 (10.8) 28 (11.2) 85 (34) 58 (23.2)
Grade 1 5 (2) 34 (13.6) 68 (27.2) 88 (35.2) 75 (30) 99 (39.6)
Grade 2 0 66 (26.4) 60 (24) 94 (37.6) 68 (27.2) 69 (27.6)
Grade 3 0 139 (55.6) 95 (38) 40 (16) 22 (8.8) 24 (9.6)
Total scores 5 583 473 396 277 309
The groups are defined as: group A, control rats; group B, anti-Thy1 nephritic rats; groups C–F, anti-Thy1 nephritic rats treated with PTX from day 13 to day
15 (group C), day 22 to 21 (group D), day 22 to 15 (group E), or day 11 to 15 (group F) of nephritis. Values for total glomerular cells are presented as mean 6
sem, and values for glomerular sclerosis represent number of glomeruli in each group (numbers in parentheses denote percentage of glomeruli). For experimental
protocol and grading of sclerosis, see the Methods section. A total of 250 glomeruli were examined from each group of 5 rats (50 glomeruli per animal).
a P , 0.01, relative to group A
b P , 0.05 and c P , 0.01, relative to group B
enhanced with 1.5% ammonium nickel sulfate (for ED-1 tured 1% agarose gels and subsequently transferred to
nylon membranes according to standard protocols [38].and a-smooth muscle actin staining). For the negative
controls, the specific antibodies were omitted. Cells were Hybridization was then performed with digoxigenin-
labeled RNA probes (method described later in this ar-identified as proliferating macrophages if they showed
positive nuclear staining for PCNA and if the nucleus ticle). The blots were developed using CSPDt (Boehrin-
ger Mannheim, Mannheim, Germany) as the substratewas completely surrounded by membrane staining for
ED-1. Cells were identified as activated proliferating for alkaline phosphatase. The intensity of the signal was
then quantitated with computerized densitometry usingMCs if they showed positive nuclear staining for PCNA
and if the nucleus was completely surrounded by cyto- the National Institutes of Health Image Program on an
Apple Macintosh computer and was normalized againstplasmic staining for a-smooth muscle actin. Calculation
of cell number was performed in a blinded fashion using the signal of glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) messages. All chemicals used for total RNAcoded samples until the analysis was complete.
isolation and Northern blot hybridization were of molec-
Immunochemical staining of mouse ular grade and were obtained from Sigma or Boehringer
anti-Thy1–IgG in glomeruli Mannheim unless otherwise specified.
For synthesis of collagen and fibronectin RNA probes,A separate experiment was performed for the analysis
of possible effects of PTX on glomerular binding of anti- cDNAs for human type I (a1), type III (a1), and type IV
(a1) collagens, and human fibronectin-1 were purchasedThy1 antibodies. A total of 12 male Wistar rats was
divided into three groups consisting of normal (N 5 4), from American Type Culture Collection (Rockville, MD,
USA). A 1.5-kb EcoRI fragment of type I (a1) collagen,nephritic (N 5 4), and pretreated nephritic (N 5 4),
with PTX treatment initiated two days before disease a 0.7-kb HindIII-EcoRI fragment of type III (a1) collagen,
a 1.4-kb PstI fragment of type IV (a1) collagen, and ainduction. Nephrectomy in two rats per group was per-
formed two hours after the initiation of nephritis. The 1.2-kb EcoRI fragment of fibronectin cDNAs were sub-
cloned, respectively, into the pBSII/SK2 vector (Strata-remaining animals were nephrectomized one day after
the induction of nephritis. Renal sections were stained gene, La Jolla, CA, USA). For synthesis of rat TGF-b1,
ICAM-1, and monocyte chemoattractant protein-1with a biotin-conjugated anti-mouse IgG (1:200; Dako)
for one hour at RT and were detected by the avidin-biotin- (MCP-1) riboprobes, cDNA fragments were first gener-
ated by reverse transcription-polymerase chain reactionperoxidase method using DAB as substrate as described
earlier in this article. (RT-PCR) from glomerular RNA of anti-Thy1–injected
rats, using the following specific primer pairs: TGF-b1, up-
Isolation of glomerular total RNA and stream, 59-TCCACAGAGAAGAACTGCTG-39 (corre-
Northern blot analysis sponding to bases 1214 to 1233) and downstream, 59-ACTT
GCAGGAGCGCACAATC-39 (corresponding to basesRenal glomeruli were isolated at various time points
after nephritis induction by graded sieving (250, 150, and 1498 to 1517) [39]; ICAM-1, upstream, 59-TCTCAGCA
GACTCTTACATC-39 (corresponding to bases 1300 to75 mm). The purity of the preparations was checked to
ensure that there was less than 5% tubular contamination 1319) and downstream, 59-ATATCCTGATCTTCCTC
TGG-39 (corresponding to bases 1587 to 1606) [40]; andin each glomerular preparation. Total RNA was then iso-
lated from the glomeruli by the acid guanidinium thiocya- MCP-1, upstream, 59-TCAGCCAGAT-GCAGTTAA
TG-39 (corresponding to bases 108 to 127) and down-nate-phenol-chloroform method [37]. Ten micrograms of
total RNA were electrophoresed on formaldehyde-dena- stream, 59-TTCTCTGTCATACTGGTCAC-39 (corre-
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sponding to bases 463 to 482) [41]. The products were
subsequently subcloned into the pGEM-dT vector (Pro-
mega, Madison, WI, USA). The cloned cDNAs were then
linearized and used as templates for in vitro transcription
of antisense digoxigenin-conjugated riboprobes, following
the supplier’s instructions (Boehringer Mannheim).
Miscellaneous measurements
Plasma and urine creatinine concentrations were mea-
sured using a standard colorimetric method (Jaffe rate
reaction). For determination of urine protein concentra-
tions, urine samples were collected from all rats in meta-
bolic cages at day 1 and day 5, respectively. The urine was
then filtered, and the proteins were precipitated with 5%
trichloroacetic acid and measured using Lowry’s method
[42]. All analyses were performed by the Department
of Laboratory Medicine, National Taiwan University
Hospital.
Statistical analysis
Data are expressed as mean 6 sem. All comparisons
were done by analysis of variance followed by Dunnett’s
t-test using the StatViewt package for the Macintosh
computer (Abacus Concepts, Berkeley, CA, USA).
RESULTS
Effect of pentoxifylline treatment on proteinuria
at day 5 of anti-Thy1 nephritis
During the course of the study, no animals showed clin-
ically adverse effects. There was no difference in body
weight, fluid intake, or urinary volume among the six
groups of rats (data not shown).
As shown in Figure 2B, the six groups had similar
levels of urinary protein excretion before the injection of
anti-Thy1 antibodies. Compared with control rats (group
A), anti-Thy1 nephritic rats (group B) demonstrated
frank proteinuria (more than an eightfold increase) on
day 1 and day 5. The groups D and E nephritic rats in
which PTX treatment was began on day 22 and the
Fig. 3. Effects of pentoxifylline (PTX) on accumulation of ED-1–group F nephritic rats in which PTX was administered
positive glomerular macrophages (A) and proliferating glomerular mac-immediately after nephritis induction showed a signifi- rophages (ED-1–positive-PCNA–positive cells; B) at various time points
cant reduction in protein excretion compared with group in rats with anti-Thy1 nephritis: control rats (h; group A), vehicle-
treated anti-Thy1 nephritic rats (d; group B), and PTX-treated anti-B on day 1 and 5. However, group C (PTX treatment
Thy1 nephritic rats (.; group E). *P , 0.05, **P , 0.01, relative tobegan two days after nephritis induction) had urinary group B.
protein levels similar to that of group B. At the end of
the experiment (day 5), plasma creatinine and calculated
creatinine clearance did not differ among groups A, B,
and E (Fig. 2A). stained sections. In contrast, in anti-Thy1 nephritic rats
treated with PTX from day 22 to day 5 (group E), the
Effect of pentoxifylline treatment on glomerular histological changes were significantly attenuated (Table
histology at day 5 1). When evaluated semiquantitatively, anti-Thy1 nephritic
rats had the highest glomerular sclerosis score on day 5Renal cortical tissue from anti-Thy1 nephritic rats
(group B) on day 5 showed prominent mesangial hyper- of nephritis, followed by, in decreasing order, group C,
group D, group F, and group E rats. The percentage ofcellularity and glomerular sclerosis on PAS/hematoxylin-
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Fig. 4. Immunohistochemical double-staining showing the effects of pentoxifylline (PTX; group E) on the number of proliferating glomerular
macrophages and activated proliferating mesangial cells in anti-Thy1 nephritis. Activated proliferating mesangial cells are identified by the red
nuclear (PCNA) and black cytoplasmic (a-smooth muscle actin) stains in vehicle-treated (A) and PTX-treated (B) rats with anti-Thy1 nephritis.
Proliferating glomerular macrophages are identified by the red nuclear (PCNA) and black cytoplasmic (ED-1) stains in vehicle-treated (C) and
PTX- treated (D) rats with anti-Thy1 nephritis. The arrowhead in (C) indicates an extraglomerular proliferating macrophage, whereas arrows in
(D) denote ED-1–positive-PCNA-negative macrophages (original magnification 3400). Publication of this figure in color was made possible by a
grant from the Ta-Tung Kidney Foundation.
Fig. 6. Immunostaining micrograph of glomeruli stained for mouse IgG in kidney sections from anti-Thy1 nephritic rats that demonstrated similar
intensity of DAB staining (B), which can be compared with (C ) a glomerulus from a nephritic rat pretreated with PTX for two days. A glomerulus
from a normal rat shows no staining (A). Nephrectomy was performed two hours after the injection of anti-Thy1 antibodies or phosphate-buffered
saline (biotin-conjugated goat anti-mouse IgG; original magnification 3400). Publication of this figure in color was made possible by a grant from
the Ta-Tung Kidney Foundation.
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glomeruli displaying moderate or severe matrix expan-
sion on day 5 was 0% in group A, 82% in group B, 62%
in group C, 54% in group D, 37% in group F, and 36%
in group E. Similarly, the total glomerular cell number on
day 5 of nephritis was also highest in anti-Thy1 nephritic
group (group B), followed by, in decreasing order, group
C, group D, group F, and group E.
Effect of pentoxifylline treatment
on glomerular macrophages
Induction of anti-Thy1 nephritis resulted in an influx
and accumulation of circulating monocytes in the glo-
merulus that began as early as two hours after the induc-
tion of nephritis (Fig. 3). The number of monocytes
(ED-1–positive) increased and peaked on day 1 and then
declined from day 2 to day 5. Treatment with PTX (group
E) reduced the number of monocytes on day 1, day 2,
and day 3 of nephritis, but did not affect the initial influx
of monocytes at two hours of nephritis. As shown in
Figures 3 and 4, approximately one third of macrophages
were actively proliferating (PCNA-positive) at two hours
of nephritis. This proportion increased to 50% on day
1 and 80% on day 2 and day 3 of nephritis. Treatment
with PTX (group E) significantly reduced the number
as well as the proportion of proliferating glomerular mac-
rophages on day 1, day 2, and day 3 of nephritis.
Effect of pentoxifylline treatment on activation and
proliferation of mesangial cells
Induction of anti-Thy1 nephritis resulted in activation
and proliferation of MCs beginning from day 3. This was
sustained well into day 5 of nephritis, at which time
more than 85% of activated MCs (a-smooth muscle actin
positive) in group B rats were also positive for PCNA,
that is, proliferating. The number of activated proliferat-
ing MCs on day 5 was reduced significantly by PTX
(group E; 230%; Figs. 4 and 5).
Nonspecific effect of pentoxifylline treatment
Pentoxifylline administered before the induction of
nephritis may interfere with anti-Thy1 nephritis in a non-
Fig. 5. Effects of pentoxifylline (PTX) on activated, proliferating mes-specific manner by reducing glomerular deposition of angial cells (a-smooth muscle actin-positive-PCNA-positive cells) at
anti-Thy1 antibodies. To determine whether treatment various time points in rats with anti-Thy1 nephritis. Symbols are: (h)
control rats (group A); (d) vehicle-treated anti-Thy1 nephritic ratswith PTX could reduce the amount of anti-Thy1 antibod-
(group B); (.) PTX-treated anti-Thy1 nephritic rats (group E). Abbre-ies reaching the glomeruli, kidney sections were stained
viation is: gcs, glomerular cross section. **P , 0.01, relative to group B.
to reveal the presence of mouse IgG. Figure 6 shows
representative glomeruli from normal rats (Fig. 6A),
anti-Thy1 rats without PTX treatment (Fig. 6B), and
day 1 of nephritis, and the same result was obtainedgroup E anti-Thy1 rats with PTX treatment (Fig. 6C) two
(data not shown).hours after nephritis induction. Glomeruli from either
untreated or treated anti-Thy1 rats contained mesangial
Effect of pentoxifylline treatment on the glomerulardeposits of IgG showing similar intensity of DAB stain-
mRNA expression of intercellular adhesioning, thus suggesting no inhibition by PTX therapy on the
molecule-1 and monocyte chemoattractant protein-1glomerular binding of anti-Thy1 antibodies. Glomeruli
Glomerular mRNA expression of ICAM-1 and MCP-1from normal rats showed no staining for mouse IgG.
The experiment was also performed with glomeruli on was up-regulated at two hours and on day 1 in anti-Thy1
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Fig. 7. Representative Northern blots demonstrating the effects of pentoxifylline (PTX) on the glomerular mRNA levels of MCP-1 and ICAM-1
in rats with anti-Thy1 nephritis at two hours, and on days 1 and 5 of disease induction. (A) Control rats (group A). (B) Vehicle-treated anti-Thy1
nephritic rats (group B). (E) PTX-treated anti-Thy1 nephritic rats (group E).
Table 2. Effect of pentoxifylline (PTX) on glomerular gene expression of monocyte chemoattractant protein-1 (MCP-1), intercellular
adhesion molecule-1 (ICAM-1), collagen, fibronectin (FN), and transforming growth factor-b1 (TGF-b1) in anti-Thy1 nephritic rats
MCP-1 ICAM-1 MCP-1 ICAM-1
Type I Type III Type IV
collagen collagen collagen FN TGF-b1
2 hours day 11Group day 15
A 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0
B 42.3 2.1 75.3 5.3 26.0 6.2 1.8 3.9 1.9
C 5.2 1.3 1.5 2.1 12.1 1.3 0.8 1.1 1.7
Groups are defined as: group A, control rats; group B, anti-Thy1 nephritic rats; group E, anti-Thy1 nephritic rats treated with PTX from day 22 to day 15.
Results are given as densitometry readings compared to that observed with glomerular RNA from control rats. Prior to this, all readings were normalized against
the messages of the housekeeping gene GAPDH. Data represent means from each group of 5 rats at indicated time points.
nephritic rats (group B). Treatment with PTX (group phosphodiesterase inhibitor, can attenuate proteinuria
E) attenuated the augmented expression of both genes and ameliorate glomerular hypercellularity and sclerosis
at two hours and on day 1. On day 5, glomerular ICAM-1 in anti-Thy1 nephritis, an experimental model closely
and MCP-1 mRNA levels were similar among groups simulating human mesangial proliferative glomerulone-
A, B, and E (Fig. 7 and Table 2). phritis. Our data indicate that this efficacy of PTX varies
with the timing of administration. Rats with anti-Thy1Effect of pentoxifylline treatment on
disease benefited most if PTX was given in the earlythe glomerular mRNA levels of type I (a1),
phase of nephritis, preferably prior to (group D), imme-III (a1), IV (a1) collagen, and fibronectin at day 5
diately after (group F), or both prior to and after induc-As shown in Figure 8 and Table 2, the induction of
tion of nephritis (group E). Pretreatment of animals wasanti-Thy1 nephritis up-regulated the glomerular mRNA
justified because PTX did not display unwanted sideexpression of type I (a1), type III (a1), and type IV (a1)
effects, such as reducing glomerular binding of anti-Thy1collagen, as well as fibronectin on day 5. Treatment with
antibodies to MCs or inhibition of initial influx of glomer-PTX (group E) attenuated the augmented expression of
all matrix genes studied on day 5. A 1.9-fold increase of ular monocyte/macrophage. Our data show that once
glomerular TGF-b1 mRNA occurred on day 5 and was the nephritis is well established (as in group C), PTX
barely affected by PTX treatment (210%, compared exerted barely any effect on proteinuria. The percentage
with group B). of glomeruli exhibiting the most severe histological changes
(grade 2 and 3) on day 5 was also higher in group C
DISCUSSION (38%) than in group D (16%), group F (10%), and group
E (9%) animals. As proteinuria often heralds activationThis study demonstrates, to our knowledge for the
first time, that pentoxifylline (PTX), a clinically available of glomerulonephritis and subsequent progression to-
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ICAM-1 that are present on the capillary endothelium
and monocytes, as well as chemokines such as MCP-1
secreted by monocytes/macrophages, might contribute
to recruitment of monocytes [15, 46, 47]. This study dem-
onstrated that rats with anti-Thy1 disease exhibited high
levels of glomerular ICAM-1 and MCP-1 mRNA during
the early phase of anti-Thy1 disease, corresponding to the
time of maximal accumulation of macrophages in the glo-
merulus. Because treatment with PTX reduced the en-
hanced glomerular mRNA expression of both ICAM-1
and MCP-1 at two hours and day 1 of nephritis, it is con-
ceivable that by reducing the expression of these mole-
cules, the recruitment of monocytes into the glomerulus
was attenuated between day 1 and day 3. In addition to
serving as a chemoattractant, MCP-1 also activates mono-
cyte superoxide anion and hydrogen peroxide production
[48]. Reactive oxygen metabolites have been shown to
mediate increased glomerular protein permeability in iso-
lated glomeruli [49]. Thus, one possible mechanism for
the reduction of proteinuria by PTX might involve either
suppression of glomerular macrophage accumulation or
inhibition of MCP-1 production by macrophages.
The mechanism by which PTX decreases the glomeru-
lar ICAM-1 and MCP-1 mRNA levels remains to be
elucidated but might involve increased levels of intracel-
lular adenosine 39,59-cyclic monophosphate (cAMP) by
inhibition of phosphodiesterase or generation of prosta-
glandins via stimulation of cyclooxygenase activity [26].
In accord with this notion, studies with cultured mono-
cytes have revealed that PTX inhibits TNF-a–augmented
expression of ICAM-1 [31], and increased levels of intra-
cellular cAMP suppress ICAM-1 and MCP-1 expression
[50, 51]. Additionally, Jocks et al have shown that prosta-
glandin E1 reduces the glomerular mRNA expression of
MCP-1 in anti-Thy1 nephritis, presumably via a cAMP
effector pathway [52].
Proliferation of recently recruited glomerular macro-
phages is an important mechanism for amplifying macro-
phage accumulation and macrophage-mediated tissue
injury in several nephritic models [5]. In this study, al-
Fig. 8. Representative Northern blots demonstrating the effects of pen- though PTX reduced the numbers of glomerular macro-
toxifylline (PTX) on the glomerular mRNA levels of type I (a1), type
phages between day 1 and day 3, the influx of monocytesIII (a1), type IV (a1) collagen, fibronectin, and TGF-b1 in rats with
anti-Thy1 nephritis on day 5 of disease induction. (A) Control rats at two hours was not affected. This observation suggests
(group A). (B) Vehicle-treated anti-Thy1 nephritic rats (group B). (E) that down-regulation of ICAM-1 and MCP-1 is not the
PTX-treated anti-Thy1 nephritic rats (group E).
only mechanism by which PTX reduces accumulation of
glomerular macrophages. In parallel with this finding,
PTX appreciably reduced the proportion of PCNA-posi-
tive macrophages on day 1 and day 3, but not at twoward glomerular sclerosis, the ability of PTX to suppress
proteinuria may have profound clinical importance. hours, of nephritis. Therefore, an additional mechanism
for the reduction of glomerular macrophages might in-Infiltration of circulating monocytes into the glomeru-
lus has been implicated in the initiation of glomerular clude direct suppression of macrophage proliferation by
PTX. Indeed, PTX has been shown to inhibit prolifera-injury in many human and experimental forms of glomer-
ulonephritis [1, 5, 43–45]. The mechanism by which mono- tion of several cell types in culture, including lympho-
cytes [29, 32–34, 53]. The fact that PTX did not affectcytes migrate to sites of renal injury is complex [1, 5].
Recent studies suggest that adhesion molecules such as the proportion of proliferating macrophages at the outset
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(2 hr) of nephritis supports the assumption that PTX cantly attenuated the augmented expression of type I (a1),
type III (a1), and type IV (a1) collagen, as well as fibro-exerts its antiproliferative activity mainly on cells that are
exposed to the various cytokines and/or growth factors nectin genes in the nephritic glomeruli. Because MCs
are the major source for various matrix proteins in thesecreted during the peak (day 1 to day 3) of the glomeru-
lar inflammation. glomerulus [12, 55], the decrease in matrix mRNA levels
might be the result of a reduction in the number ofMediation of myofibroblast transformation and re-
bound proliferation of MCs in anti-Thy1 nephritis likely activated proliferating MCs by PTX. However, the dec-
rement of matrix protein mRNA levels [ranging frominvolves several mechanisms, which incorporate a wide
array of cytokines and growth factors secreted by infil- 253% for type I (a1) collagen to 2 78% for type III
(a1) collagen; Table 2] was greater than the decrementtrating macrophages and resident glomerular cells, pri-
marily MCs [5, 8, 54]. Among those, PDGF and basic of activated proliferating MCs on day 5 (230%; Fig. 5).
We therefore surmise that the reduction of the glomeru-fibroblast growth factor have been implicated to play
pivotal roles in the anti-Thy1 model [7, 13, 17]. Pre- lar mRNA levels of collagens and fibronectin by PTX
in anti-Thy1 nephritis occurs as a result of suppressionviously, we have shown that PTX inhibits both steady-
state and PDGF-stimulated proliferation of cultured of transcriptional activity and/or mRNA stability.
In summary, this study demonstrates that the clinicallyMCs [34]. This study further demonstrated that PTX in
vivo reduced the numbers of activated macrophages in available phosphodiesterase inhibitor PTX reduces accu-
mulation and proliferation of glomerular macrophages,the early phase of nephritis and also decreased the num-
bers of activated MCs on day 5. Because MCs are respon- attenuates proteinuria, suppresses activation and prolif-
eration of MCs, and ameliorates glomerular sclerosis insible for the production of a variety of extracellular ma-
trix proteins within the glomerulus [12, 55], suppression rats with anti-Thy1 disease. The mechanism by which
PTX acts might be, at least in part, ascribed to its abilityof their activation and proliferation may contribute sig-
nificantly to the amelioration of glomerular sclerosis. to suppress glomerular ICAM-1 and MCP-1 mRNA lev-
els in the early phase and extracellular matrix proteinOne potential mechanism by which PTX may affect MC
proliferation is generation of intracellular cAMP [26]. mRNA levels on day 5 of nephritis. These results suggest
that administration of PTX in vivo may have promise asIn agreement with this notion, the selective inhibitors
of phosphodiesterase isozymes, lixazinone, and rolipram an anti-inflammatory, anti-proliferative, and anti-fibrotic
agent in the treatment of acute phases or relapses ofhave been shown to inhibit MC proliferation by blocking
the mitogen-activated protein kinase pathway via a mesangial proliferative glomerulonephritis.
cAMP-dependent cascade [56]. Alternatively, PTX may
have other signaling pathways. Yang, Chuen, and Shaio ACKNOWLEDGMENTS
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